Tags

Type your tag names separated by a space and hit enter

[Urinary methylmalonic acid excretion and clinical features in megaloblastic anemia due to vitamin B12 deficiency].
Rinsho Ketsueki. 1989 Jun; 30(6):835-9.RK

Abstract

Urinary methylmalonic acid (MMA) excretion in megaloblastic anemia due to vitamin B12 (B12) deficiency was studied using a colorimetric method. Average MMA excretion in 20 patients with untreated B12 deficiency was 164 mg/day, whereas it increased to 518 mg/day following oral administration of 10 g L-valine. Urinary MMA correlated significantly with platelet number, erythroblast percentage and deoxyuridine suppression test, while no correlation was found with hemoglobin, leukocyte number, reticulocyte, serum LDH, serum B12 and folate concentration. Patients with neurological disturbances excreted significantly larger amounts of MMA than those without neurological disorders. The results also indicated that MMA could be a useful adjunct for differentiation of megaloblastic anemia from myelodysplastic syndromes showing marked megaloblastic changes.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

jpn

PubMed ID

2795894

Citation

Yamauchi, H, et al. "[Urinary Methylmalonic Acid Excretion and Clinical Features in Megaloblastic Anemia Due to Vitamin B12 Deficiency]." [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology, vol. 30, no. 6, 1989, pp. 835-9.
Yamauchi H, Omine M, Tsukamoto N, et al. [Urinary methylmalonic acid excretion and clinical features in megaloblastic anemia due to vitamin B12 deficiency]. Rinsho Ketsueki. 1989;30(6):835-9.
Yamauchi, H., Omine, M., Tsukamoto, N., Katahira, H., Karasawa, M., Sugita, Y., Yatabe, H., Iwata, N., & Maekawa, T. (1989). [Urinary methylmalonic acid excretion and clinical features in megaloblastic anemia due to vitamin B12 deficiency]. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 30(6), 835-9.
Yamauchi H, et al. [Urinary Methylmalonic Acid Excretion and Clinical Features in Megaloblastic Anemia Due to Vitamin B12 Deficiency]. Rinsho Ketsueki. 1989;30(6):835-9. PubMed PMID: 2795894.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Urinary methylmalonic acid excretion and clinical features in megaloblastic anemia due to vitamin B12 deficiency]. AU - Yamauchi,H, AU - Omine,M, AU - Tsukamoto,N, AU - Katahira,H, AU - Karasawa,M, AU - Sugita,Y, AU - Yatabe,H, AU - Iwata,N, AU - Maekawa,T, PY - 1989/6/1/pubmed PY - 1989/6/1/medline PY - 1989/6/1/entrez SP - 835 EP - 9 JF - [Rinsho ketsueki] The Japanese journal of clinical hematology JO - Rinsho Ketsueki VL - 30 IS - 6 N2 - Urinary methylmalonic acid (MMA) excretion in megaloblastic anemia due to vitamin B12 (B12) deficiency was studied using a colorimetric method. Average MMA excretion in 20 patients with untreated B12 deficiency was 164 mg/day, whereas it increased to 518 mg/day following oral administration of 10 g L-valine. Urinary MMA correlated significantly with platelet number, erythroblast percentage and deoxyuridine suppression test, while no correlation was found with hemoglobin, leukocyte number, reticulocyte, serum LDH, serum B12 and folate concentration. Patients with neurological disturbances excreted significantly larger amounts of MMA than those without neurological disorders. The results also indicated that MMA could be a useful adjunct for differentiation of megaloblastic anemia from myelodysplastic syndromes showing marked megaloblastic changes. SN - 0485-1439 UR - https://www.unboundmedicine.com/medline/citation/2795894/[Urinary_methylmalonic_acid_excretion_and_clinical_features_in_megaloblastic_anemia_due_to_vitamin_B12_deficiency]_ DB - PRIME DP - Unbound Medicine ER -